The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth
Open accessAbstract
The transcription factor signal transducer and activator of transcription 3 (Stat3) is constitutively activated in a variety of cancers including squamous cell carcinoma of the head and neck (SCCHN). Previous investigations have demonstrated that activated Stat3 contributes to a loss of growth control and transformation. To investigate the therapeutic potential of blocking Stat3 in cancer cells, we developed a transcription factor decoy to selectively abrogate activated Stat3. The Stat3 decoy was composed of a 15-mer double-stranded oligonucleotide, which corresponded closely to the Stat3 response element within the c-fos promoter. The Stat3 decoy bound specifically to activated Stat3 and blocked binding of Stat3 to a radiolabeled Stat3 binding element. By contrast, a mutated version of the decoy that differed by only a single base pair did not bind the activated Stat3 protein. Treatment of head and neck cancer cells with the Stat3 decoy inhibited proliferation and Stat3-mediated gene expression, but did not decrease the proliferation of normal oral keratinocytes. Thus, disruption of activated Stat3 by using a transcription factor decoy approach may serve as a novel therapeutic strategy for cancers characterized by constitutive Stat3 activation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nucleic acid–based drugs, including decoy oligonucleotides and, perhaps, G-quartet oligonucleotides, have been identified that inhibit STAT3-mediated gene expression and inhibit growth of different cancer cell lines (Leong et al., 2003; Lewis et al., 2008; Sun et al., 2008; Shen et al., 2009; Zhang et al., 2013b; Liu et al., 2014; Sen et al., 2014).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Leong et al., 2003
Citations
Cites
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
The role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro‐Cacho, C., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S. J., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204349 · Cited by 756
A common nuclear signal transduction pathway activated by growth factor and cytokine receptors.
Sadowski, H., Shuai, K., Darnell, J., & Gilman, M. (1993) · Science · doi:10.1126/science.8397445 · Cited by 682
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Jain, M., Arvanitis, C., Chu, K., Dewey, W. C., Leonhardt, E. A., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 661
Research works printed but not linked: 8
- T Kijima, H Niwa, R A Steinman, S D Drenning, W E Gooding, A L Wentzel, J Rubin Grandis Cell Growth Differ 13, 355–362 (2002).
- B L Riser, R Mitra, D Perry, V Dixit, J Varani Cancer Res 49, 6123–6129 (1989).
- D S Heo, C Snyderman, S M Gollin, S Pan, E Walker, R Deka, E L Barnes, J T Johnson, R B Herberman, T L Whiteside Cancer Res 49, 5167–5175 (1989).
- H W Sharma, R Narayanan Anticancer Res 16, 589–596 (1996).
- H W Sharma, J R Perez, K Higgins-Sochaski, R Hsiao, R Narayanan Anticancer Res 16, 61–69 (1996).
- Y Sawa, R Morishita, K Suzuki, K Kagisaki, Y Kaneda, K Maeda, K Kadoba, H Matsuda Circulation 96,(Suppl.), II-280–II-284, ; discussion, II-285. (1997).
- G Niu, R Heller, R Catlett-Falcone, D Coppola, M Jaroszeski, W Dalton, R Jove, H Yu Cancer Res 59, 5059–5063 (1999).
- M Masuda, M Suzui, R Yasumatu, T Nakashima, Y Kuratomi, K Azuma, K Tomita, S Komiyama, I B Weinstein Cancer Res 62, 3351–3355 (2002).
Cited by
Sorted by citations
Items 301–341 of 341
Choudhary, N. K., Sharma, S. N., Das, G., Ghosh, A., Bagale, S. S., Sinha, S., & Gore, K. R. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00158 · Cited by 1
B-MYB (MYBL2): from cell cycle regulator to an oncogenic player
Miranda, A., Oliveira, P. A., Mergny, J., & Cruz, C. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189697 · Cited by 1
Halachmi, S., AITKEN, K. J., Szybowska, M., Sabha, N., Dessouki, S., Lorenzo, A. J., Tse, D., & Bägli, D. (2007) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2007.01.047 · Cited by 1
Brain Tumor Immunology and Immunotherapy
Glick, R. P., Lichtor, T., & Heimberger, A. B. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5316-3.00099-x · Cited by 1
Mayorga, D. C., Parra, M. R., & Aristizábal, F. (2020) · Revista Colombiana de Biotecnología · doi:10.15446/rev.colomb.biote.v22n2.73114 · Cited by 1
Hajilou, Z., Solhi, R., Shokouhian, B., Torabi, S., Heydari, Z., Farzaneh, Z., Bahadori, S., Piryaei, A., Hassan, M., Nussler, A. K., et al. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2024.56 · Cited by 1
Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy
Santos, F. P. D. S., Hazan‐Halevy, I., & Estrov, Z. E. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0730-0_13 · Cited by 1
STAT3 as a Major Contributor to Chemoresistance
Lee, D. S., Grandis, J. R., & Johnson, D. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813753-6.00007-x · Cited by 1
Self-citationNovel mechanisms of Stat3 activation
Arulanandam, R. (2010) · QSpace (Queen's University Library) · Cited by 1
EGFRvIII Expression and Signaling in head and neck squamous cell carcinoma
Wheeler, S. E. (2012) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Imaging Mass Spectrometry for Drugs and Metabolites
Oppenheimer, S. R. (2013) · doi:10.1002/9781118516157.ch11
Barry, S. P. (2009) · UCL Discovery (University College London)
Re: Decreased STAT1 Expression by Promoter Methylation in Squamous Cell Carcinogenesis
Wong, T., Liu, X.-B., Ng, R. W.-M., Wei, W., & Yuen, A. P. W. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm091
Stat3 and Tumor Cell Proliferation
Fakultät, P.-N. (2004)
Drug Discovery Approaches Targeting the JAK/STAT Pathway
Seidel, H. M., & Rosen, J. (2003) · Springer eBooks · doi:10.1007/978-94-017-3000-6_45
Huang, W. (2014) · IUScholarWorks (Indiana University) · doi:10.7912/c2/310
Prevention and Treatment of Head and Neck Cancer with Natural Compound Inhibitors of STAT3
Leeman‐Neill, R. J. (2008) · D-Scholarship@Pitt (University of Pittsburgh)
Developing Inhibitors of STAT3: Targeting Downstream of the Kinases for Treating Disease
Lewis, A. M., Ball, D. P., Rana, R., Park, J. S., Rosa, D. A., Lai, P., Gómez‐Biagi, R. F., & Gunning, P. T. (2015) · doi:10.1002/9783527683031.ch12
Potential Molecular Targets: From Bench to Bedside
Matta, A., & Ralhan, R. (2012) · Head and neck cancer clinics · doi:10.1007/978-81-322-2574-4_1
Functional genomics of the VNN1 gene
Diepeveen, L. A. (2013) · UWA Profiles and Research Repository (UWA)
Modulation of Regulatory T Cells by Cytokines
Pillemer, B. B. L. (2007) · D-Scholarship@Pitt (University of Pittsburgh)
Zhang, P. (2013) · OhioLink ETD Center (Ohio Library and Information Network)
KANSER GELİŞİMİNDE İNFLAMASYONUN ROLÜ
Yıldırım, I. (2019) · ANADOLU UNIVERSITY JOURNAL OF SCIENCE AND TECHNOLOGY –C Life Sciences and Biotechnology · doi:10.18036/aubtdc.412520
ROLES AND REGULATION OF STAT3 IN INNATE IMMUNITY
Hsia, H.-C. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/wgan-wy61
miR-17-5p Combined with Epirubicin Inhibits the Progression of Breast Cancer CellsPreprint
Zhao, L., Zhu, Z., Du, J., Zhao, Y., & Fan, D. (2020) · Research Square · doi:10.21203/rs.3.rs-127804/v1
STAT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Yang, Y., & Shi, Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00005-5
Response: Re: Decreased STAT1 Expression by Promoter Methylation in Squamous Cell Carcinogenesis
Grandis, J. R., Califano, J. A., Smith, I., & Mithani, S. K. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm093
Self-citationOkamoto, T., Inozume, T., Mitsui, H., Kanzaki, M., Harada, K., Shibagaki, N., & Shimada, S. (2023) · doi:10.1158/1535-7163.c.6531947
Okamoto, T., Inozume, T., Mitsui, H., Kanzaki, M., Harada, K., Shibagaki, N., & Shimada, S. (2023) · doi:10.1158/1535-7163.c.6531947.v1
Li, C., Zang, Y., Sen, M., Leeman‐Neill, R. J., Man, D., Grandis, J. R., & Johnson, D. E. (2023) · doi:10.1158/1535-7163.c.6532199.v1
Self-citationLi, C., Zang, Y., Sen, M., Leeman‐Neill, R. J., Man, D., Grandis, J. R., & Johnson, D. E. (2023) · doi:10.1158/1535-7163.c.6532199
Self-citationWang, Y., Ma, X., Yan, S., Shen, S., Zhu, H., Gu, Y., Wang, H., Qin, G., & Yu, Q. (2023) · doi:10.1158/0008-5472.c.6499092.v1
Zhang, L., Gao, L., Yang, L., Lin, G., Shao, Y., Ji, K., Yu, H. N., Hu, J., Kalvakolanu, D. V., Kopecko, D. J., et al. (2023) · doi:10.1158/1078-0432.c.6518118
Zhang, L., Gao, L., Yang, L., Lin, G., Shao, Y., Ji, K., Yu, H. N., Hu, J., Kalvakolanu, D. V., Kopecko, D. J., et al. (2023) · doi:10.1158/1078-0432.c.6518118.v1
Boehm, A. L. (2007) · D-Scholarship@Pitt (University of Pittsburgh)
Geinguenaud, F. (2015) · theses.fr (ABES) · doi:10.70675/8b4ba947zac77z4118z8843z0357ebbb66e9
Feng, X., Li, N., Chen, X., Cao, X., Dai, J., Xiong, S., & Yuan, Z. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118532
BindingDB (2014) · UC San Diego · doi:10.7270/q2d2202p
Metadata
- Authors
- Leong, P. L., Andrews, G. A., Johnson, D. E., Dyer, K. F., Xi, S., Mai, J. C., Robbins, P. D., Gadiparthi, S., Burke, N. A., Watkins, S. F., & Grandis, J. R.
- Affiliations
- University of Pittsburgh (US)
- Departments of Otolaryngology, Medicine, Pharmacology, Molecular Genetics and Biochemistry, and Cell Biology and Physiology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15260
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-03-14
- Volume
- 100
- Issue
- 7
- Pages
- 4138-4143
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC153061
- OpenAlex
- W2143812692
- Cited by
- 340
- References
- 47
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 13 · 2023: 11 · 2022: 6 · 2021: 8 · 2020: 13 · 2019: 14 · 2018: 10 · 2017: 3 · 2016: 8 · 2015: 20 · 2014: 16 · 2013: 23 · 2012: 25
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- American Academy of Otolaryngology-Head and Neck Surgery
- National Institutes of Health
- National Cancer Institute (CA77308, R01CA077308)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- STAT3, transcription factor decoy, head and neck squamous cell carcinoma, c-fos promoter, constitutive STAT3 activation, tumor cell proliferation, oral keratinocytes
- MeSH terms
- Carcinoma, Squamous Cell, Cell Division, DNA-Binding Proteins, Head and Neck Neoplasms, Humans, Luciferases, Tumor Cells, Cultured, Trans-Activators, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Oligodeoxyribonucleotides, Antisense, STAT3 Transcription Factor, bcl-X Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
